Literature DB >> 24837031

Rate of Chiari I malformation in children of mothers with depression with and without prenatal SSRI exposure.

Rebecca C Knickmeyer1, Samantha Meltzer-Brody1, Sandra Woolson1, Robert M Hamer2, J Keith Smith3, Kenneth Lury3, John H Gilmore1.   

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are frequently prescribed to pregnant women. Therefore, research on in utero exposure to SSRIs can be helpful in informing patients and clinicians. The aim of this retrospective two-cohort study was to determine whether there is a statistically significant increase in Chiari I malformations (CIM) in children exposed to SSRIs during pregnancy. A total of 33 children whose mothers received a diagnosis of depression and took SSRIs during pregnancy (SSRI-exposed cohort) were matched to 66 children with no history of maternal depression and no SSRI exposure. In addition, 30 children whose mothers received a diagnosis of depression, but did not receive antidepressants during pregnancy (history of maternal depression cohort), were matched to 60 children with no history of maternal depression and no SSRI exposure. Main outcome was presence/absence of CIM on MRI scans at 1 and/or 2 years of age. Scans were reviewed by two independent neuroradiologists who were blind to exposure status. The SSRI-exposed children were significantly more likely to be classified as CIM than comparison children with no history of maternal depression and no SSRI exposure (18% vs 2%, p=0.003, OR estimate 10.32, 95% Wald confidence limits 2.04-102.46). Duration of SSRI exposure, SSRI exposure at conception, and family history of depression increased the risk. The history of maternal depression cohort did not differ from comparison children with no history of maternal depression and no SSRI exposure in occurrence of CIM (7% vs 5%, p=0.75, OR estimate 1.44, 95% Wald confidence limits 0.23-7.85). Replication is needed, as is additional research to clarify whether SSRIs directly impact risk for CIM or whether this relationship is mediated by severity of depressive symptoms during pregnancy. We would discourage clinicians from altering their prescribing practices until such research is available.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24837031      PMCID: PMC4207341          DOI: 10.1038/npp.2014.114

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  55 in total

1.  Chiari I malformation redefined: clinical and radiographic findings for 364 symptomatic patients.

Authors:  T H Milhorat; M W Chou; E M Trinidad; R W Kula; M Mandell; C Wolpert; M C Speer
Journal:  Neurosurgery       Date:  1999-05       Impact factor: 4.654

2.  Increasing use of antidepressants in pregnancy.

Authors:  William O Cooper; Mary E Willy; Stephen J Pont; Wayne A Ray
Journal:  Am J Obstet Gynecol       Date:  2007-06       Impact factor: 8.661

3.  The timing of maternal depressive symptoms and mothers' parenting practices with young children: implications for pediatric practice.

Authors:  Kathryn Taaffe McLearn; Cynthia S Minkovitz; Donna M Strobino; Elisabeth Marks; William Hou
Journal:  Pediatrics       Date:  2006-07       Impact factor: 7.124

Review 4.  Antidepressant use in pregnancy: a critical review focused on risks and controversies.

Authors:  N Byatt; K M Deligiannidis; M P Freeman
Journal:  Acta Psychiatr Scand       Date:  2012-12-14       Impact factor: 6.392

Review 5.  Hydrocephalus and Chiari type I malformation.

Authors:  Concezio Di Rocco; Paolo Frassanito; Luca Massimi; Simone Peraio
Journal:  Childs Nerv Syst       Date:  2011-09-17       Impact factor: 1.475

6.  Natural history of Chiari malformation Type I following decision for conservative treatment.

Authors:  Jennifer Strahle; Karin M Muraszko; Joseph Kapurch; J Rajiv Bapuraj; Hugh J L Garton; Cormac O Maher
Journal:  J Neurosurg Pediatr       Date:  2011-08       Impact factor: 2.375

7.  Outcomes in pediatric patients with Chiari malformation Type I followed up without surgery.

Authors:  David Benglis; Derek Covington; Ritwik Bhatia; Sanjiv Bhatia; Mohamed Samy Elhammady; John Ragheb; Glenn Morrison; David I Sandberg
Journal:  J Neurosurg Pediatr       Date:  2011-04       Impact factor: 2.375

8.  Natural history of Chiari type I malformation in children.

Authors:  Luca Massimi; Massimo Caldarelli; Paolo Frassanito; Concezio Di Rocco
Journal:  Neurol Sci       Date:  2011-12       Impact factor: 3.307

9.  Maternal use of selective serotonin reuptake inhibitors during pregnancy and neonatal bone density.

Authors:  Gal Dubnov-Raz; Harri Hemilä; Yael Vurembrand; Jacob Kuint; Ayala Maayan-Metzger
Journal:  Early Hum Dev       Date:  2011-09-03       Impact factor: 2.079

Review 10.  The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists.

Authors: 
Journal:  Obstet Gynecol       Date:  2009-09       Impact factor: 7.661

View more
  4 in total

Review 1.  Advances in Epidemiological Methods and Utilisation of Large Databases: A Methodological Review of Observational Studies on Central Nervous System Drug Use in Pregnancy and Central Nervous System Outcomes in Children.

Authors:  Zixuan Wang; Phoebe W H Ho; Michael T H Choy; Ian C K Wong; Ruth Brauer; Kenneth K C Man
Journal:  Drug Saf       Date:  2019-04       Impact factor: 5.606

Review 2.  Safety of Selective Serotonin Reuptake Inhibitors in Pregnancy: A Review of Current Evidence.

Authors:  Sura Alwan; Jan M Friedman; Christina Chambers
Journal:  CNS Drugs       Date:  2016-06       Impact factor: 5.749

3.  Antenatal depression, treatment with selective serotonin reuptake inhibitors, and neonatal brain structure: A propensity-matched cohort study.

Authors:  Shaili C Jha; Samantha Meltzer-Brody; Rachel J Steiner; Emil Cornea; Sandra Woolson; Mihye Ahn; Audrey R Verde; Robert M Hamer; Hongtu Zhu; Martin Styner; John H Gilmore; Rebecca C Knickmeyer
Journal:  Psychiatry Res Neuroimaging       Date:  2016-05-24       Impact factor: 2.376

4.  Functional Connectivity Disruption in Neonates with Prenatal Marijuana Exposure.

Authors:  Karen Grewen; Andrew P Salzwedel; Wei Gao
Journal:  Front Hum Neurosci       Date:  2015-11-04       Impact factor: 3.169

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.